Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine Adjuvant Therapy for HCC
NCT00561522Phase 3Unknown
- Sponsor
- Fudan University
- Start
- Nov 2007
- Primary completion
- Jul 2012
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of capecitabine in hepatocellular carcinoma (HCC) (2 arms), sponsored by Fudan University. Primary endpoints: Disease-Free Survival at 4 years and Overall Survival at 4 years. Status: unknown.
02
Drugs
capecitabine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00561522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00561522.